Key facts
- It has raised $11.6M; the latest was Later Stage VC in Feb 2026.
- Notable investors include European Innovation Council, MedTech Innovator, High-Tech Gründerfonds, Elron Ventures, Interactive Ventures Holdings — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tripair
- ·The full record, as it builds
Funding rounds
No funding rounds for Tripair are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tripair
Developer of an adaptive tricuspid valve repair device designed to treat structural heart valve diseases. The company's device prevents the backflow of blood in functional mitral regurgitation, which is caused by enlargement of the heart due to a heart attack or heart failure, enabling healthcare professionals to treat heart patients with a less invasive procedure.
- Sector
- Healthcare
- HQ
- Hilden, Germany
- Founded
- 2013
- Employees
- 21
- Website
- tripairtechnology.com/
- Ownership
- Privately Held (backing)
Tripair doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tripair shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tripair in its N-PORT filings yet. We sweep new filings monthly.